These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16444181)

  • 1. Acromegaly - evolving strategies.
    Popovic V
    Pediatr Endocrinol Rev; 2004 Aug; 1 Suppl 3():496-500. PubMed ID: 16444181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy for the syndromes of GH excess.
    Arosio M; Cannavò S; Epaminonda P; Ronchi C; Chiodini I; Adda G
    J Endocrinol Invest; 2003; 26(10 Suppl):36-43. PubMed ID: 15497658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for the diagnosis and treatment of acromegaly: a Canadian perspective.
    Patel YC; Ezzat S; Chik CL; Rorstad OP; Serri O; Ur E; Wilkins GE
    Clin Invest Med; 2000 Jun; 23(3):172-87. PubMed ID: 10911548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Possibilities of medical treatment in acromegaly].
    Cáp J; Nemecek S; Rezácová M; Cerman J
    Cas Lek Cesk; 2005; 144 Suppl 3():33-4, 36-7. PubMed ID: 16335261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are there alternative tests for diagnosis of acromegaly?
    Popovic V
    J Endocrinol Invest; 2005; 28(11 Suppl International):73-4. PubMed ID: 16625850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The critical parameters in GH excess.
    Sheppard MC
    J Endocrinol Invest; 2005; 28(5 Suppl):92-5. PubMed ID: 16114283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.
    Clemmons DR; Chihara K; Freda PU; Ho KK; Klibanski A; Melmed S; Shalet SM; Strasburger CJ; Trainer PJ; Thorner MO
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4759-67. PubMed ID: 14557452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug insight: Primary medical therapy of acromegaly.
    Katznelson L
    Nat Clin Pract Endocrinol Metab; 2006 Feb; 2(2):109-17; quiz following 117. PubMed ID: 16932265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GH and mortality in acromegaly.
    Sheppard MC
    J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
    Bastemir M; Akin F; Yaylali GF
    Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current diagnostic guidelines for biochemical diagnosis of acromegaly.
    Ferone D; Resmini E; Bocca L; Giusti M; Barreca A; Minuto F
    Minerva Endocrinol; 2004 Dec; 29(4):207-23. PubMed ID: 15765030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy in acromegaly.
    Sherlock M; Woods C; Sheppard MC
    Nat Rev Endocrinol; 2011 May; 7(5):291-300. PubMed ID: 21448141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs.
    Chanson P
    Neuroendocrinology; 2016; 103(1):50-8. PubMed ID: 25677539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current therapy and drug pipeline for the treatment of patients with acromegaly.
    Kumar SS; Ayuk J; Murray RD
    Adv Ther; 2009 Apr; 26(4):383-403. PubMed ID: 19444656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical evidence in favor of revising Cortina criteria.
    Webb SM; Sucunza N; Barahona MJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):84-6. PubMed ID: 16625854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
    Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice.
    Bielohuby M; Roemmler J; Manolopoulou J; Johnsen I; Sawitzky M; Schopohl J; Reincke M; Wolf E; Hoeflich A; Bidlingmaier M
    Exp Biol Med (Maywood); 2009 Aug; 234(8):1002-9. PubMed ID: 19491373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.